Theravance Biopharma Equity 2024

Theravance Biopharma Aktienanalyse

What does Theravance Biopharma do?

Theravance Biopharma Inc is a company that was founded in 2014 and is headquartered in South San Francisco, California. The company is a spin-off of Theravance Inc, which was founded in 1996 and specialized in the development of drugs for respiratory diseases and infections. The business model of Theravance Biopharma is to develop and market innovative drugs for severe respiratory diseases, infections, and immunological disorders. The company works closely with its partners and scientific network to discover, develop, and market new drugs. Theravance Biopharma is divided into several business units, including Theravance Biopharma R&D, which focuses on drug discovery and development, and Theravance Biopharma Commercialization, which focuses on marketing Theravance's products. The company has developed and launched a number of products, including the branded products Vibativ and Velusetrag. Vibativ is an antibiotic used to treat severe lung infections and other infections, while Velusetrag was developed for the treatment of chronic constipation in patients with gastrointestinal disorders such as irritable bowel syndrome. The company also has a broad pipeline of products in various stages of development. This includes drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD), autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis, as well as infections such as MRSA and pneumococcal. Theravance Biopharma has also formed a strong partnership with GSK (GlaxoSmithKline), one of the world's leading pharmaceutical companies. The two companies are working together to develop drugs to help patients with severe respiratory diseases, infections, and immune disorders. In summary, Theravance Biopharma is an innovative company that focuses on the discovery, development, and commercialization of drugs for the treatment of severe respiratory diseases, infections, and immune disorders. The company has a strong pipeline of products in various stages of development and a strong partnership with GSK to continue providing innovative solutions for patients with severe illnesses. Theravance Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Theravance Biopharma's Equity

Theravance Biopharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Theravance Biopharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Theravance Biopharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Theravance Biopharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Theravance Biopharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Theravance Biopharma stock

What is the equity of Theravance Biopharma this year?

Theravance Biopharma has equity of 212.99 M USD this year.

What was the equity of Theravance Biopharma compared to the previous year?

The equity of Theravance Biopharma has increased/decreased by -51.79% decreased compared to the previous year.

What impact does a high equity have on investors of Theravance Biopharma?

A high equity is advantageous for investors of Theravance Biopharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Theravance Biopharma?

A low equity can be a risk for investors of Theravance Biopharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Theravance Biopharma affect the company?

An increase in equity of Theravance Biopharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Theravance Biopharma affect the company?

A reduction in equity of Theravance Biopharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Theravance Biopharma?

Some factors that can affect the equity of Theravance Biopharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Theravance Biopharma so important for investors?

The equity of Theravance Biopharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Theravance Biopharma take to change the equity?

To change equity, Theravance Biopharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Theravance Biopharma pay?

Over the past 12 months, Theravance Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theravance Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Theravance Biopharma?

The current dividend yield of Theravance Biopharma is .

When does Theravance Biopharma pay dividends?

Theravance Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theravance Biopharma?

Theravance Biopharma paid dividends every year for the past 0 years.

What is the dividend of Theravance Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theravance Biopharma located?

Theravance Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theravance Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theravance Biopharma from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Theravance Biopharma pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Theravance Biopharma in the year 2023?

In the year 2023, Theravance Biopharma distributed 0 USD as dividends.

In which currency does Theravance Biopharma pay out the dividend?

The dividends of Theravance Biopharma are distributed in USD.